Arrowhead Pharmaceuticals Overview

  • Founded
  • 1989
Founded
  • Status
  • Public
  • Employees
  • 232
Employees
  • Stock Symbol
  • ARWR
Stock Symbol
  • Investments
  • 9
  • Share Price
  • $85.98
  • (As of Thursday Closing)

Arrowhead Pharmaceuticals General Information

Description

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Contact Information

Formerly Known As
InterActive Group, Arrowhead Research
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 177 East Colorado Boulevard
  • Suite 700
  • Pasadena, CA 91105
  • United States
+1 (626) 000-0000

Arrowhead Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrowhead Pharmaceuticals Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$85.98 $85.84 $32.86 - $92.60 $8.95B 104M 733K -$1.07

Arrowhead Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 30-Sep-2020 FY 2019 30-Sep-2019 FY 2018 30-Sep-2018
EV 6,598,016 4,138,470 2,448,128 1,628,747
Revenue 89,122 87,992 168,796 16,142
EBITDA (114,089) (87,799) 65,630 (50,797)
Net Income (109,594) (84,553) 67,975 (54,450)
Total Assets 756,795 522,504 349,845 111,610
Total Debt 23,800 21,138 0 2,325
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arrowhead Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arrowhead Pharmaceuticals‘s full profile, request access.

Request a free trial

Arrowhead Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to tr
Biotechnology
Pasadena, CA
232 As of 2020
00.000
000000 - 000 00.000

0000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
000000000 00.000

0000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
000000000000000
Cambridge, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arrowhead Pharmaceuticals Competitors (55)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000 - 000 0000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000000 00000
000000 00000000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
You’re viewing 5 of 55 competitors. Get the full list »

Arrowhead Pharmaceuticals Executive Team (14)

Name Title Board Seat Contact Info
Christopher Anzalone Ph.D Chief Executive Officer & Board Member
Kenneth Myszkowski Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
James Hassard Executive
Vincent Anzalone Vice President & Head of Investor Relations
Thomas Schluep Vice President of Program Management
You’re viewing 5 of 14 executive team members. Get the full list »

Arrowhead Pharmaceuticals Board Members (10)

Name Representing Role Since
00000000000 00000000 00.0 Arrowhead Pharmaceuticals Chief Executive Officer & Board Member 000 0000
00000000 00000 00 Self Chairman & Board Member 000 0000
00000 0000000 00.0 Self Board Member 000 0000
0000000 00000 00.0 Self Board Member 000 0000
000 00000000 00 Arrowhead Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Arrowhead Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrowhead Pharmaceuticals Investments & Acquisitions (9)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (0000 000 05-Mar-2015 000000000000000000 0000 Biotechnology 00000000000 00000000 00.0
00000 000000000000 11-Apr-2012 000000000000000000 000 Drug Discovery
00000 0000000 (000 24-Oct-2011 000000000000000000 00.00 Drug Delivery 00000000000 00000000 00.0
000000 15-Jul-2009 000000000000000000 Electrical Equipment
Masa Energy 29-Dec-2008 Merger/Acquisition 00000 Holding Companies
You’re viewing 5 of 9 investments and acquisitions. Get the full list »

Arrowhead Pharmaceuticals Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 15-Jul-2009 000000000000000000 Completed
  • 000000000 00000000
000000 17-Jun-2008 00000 00000 00 000 Completed
  • 2 buyers
0000000 0000000000 16-Oct-2006 00000 00000 00 000.00 Completed
  • 2 buyers
0000000 0000000000 04-Jun-2004 000000000000000000 Completed
  • 000000000 00000000
Unidym Early Stage VC 000 Completed
To view Arrowhead Pharmaceuticals’s complete exits history, request access »